Prinzmetal Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Prinzmetal angina markets are expected to exhibit a CAGR of 3.8% during 2024-2034.
The Prinzmetal angina market has been comprehensively analyzed in IMARC's new report titled "Prinzmetal Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Prinzmetal angina, also known as variant or vasospastic angina, refers to a form of chest pain or discomfort, which occurs due to a temporary narrowing of the coronary arteries. It is primarily caused by spasms or constrictions of the coronary arteries that can arise even when the person is at rest, making it distinct from other forms of angina. The symptoms of this condition are similar to those of classic angina and include chest pain or discomfort, often described as a tightness, pressure, or squeezing sensation in the chest. The pain typically occurs during rest or sleep and can be more severe. It often happens in episodes, and the pain can also radiate to the neck, jaw, shoulder, or arm. The diagnosis of Prinzmetal angina involves electrocardiograms (ECGs) during chest pain, which can show characteristic changes, such as transient ST-segment elevation. Coronary angiography may also be recommended to assess the condition of the coronary arteries and rule out various other underlying disorders.
The increasing incidences of endothelial dysfunction due to various risk factors, such as smoking, high cholesterol levels, elevated blood pressure, etc., resulting in abnormal responses to certain stimuli and narrowing of blood vessels, are primarily driving the Prinzmetal angina market. In addition to this, the inflating utilization of efficacious medications like calcium channel blockers, nitrates, nitroglycerin, etc., that are aimed at mitigating symptoms and averting further ischemic episodes is creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle adjustments and risk factor management strategies, due to their pivotal role in minimizing the frequency and intensity of vasospastic events, is also bolstering the market growth. Apart from this, the rising usage of cardiac rehabilitation programs, which help in enhancing cardiovascular resilience, optimizing exercise tolerance, and ameliorating overall cardiac function, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of invasive procedures, such as coronary angiography, since they facilitate precise visualization and diagnosis of vasospasms in patients, is also augmenting the market growth. Furthermore, the escalating application of gene-based interventions, entailing the introduction of functional genetic material into cells to rectify or replace the aberrant genes responsible for the condition, is expected to drive the Prinzmetal angina market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Prinzmetal angina market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Prinzmetal angina and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Prinzmetal angina market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Prinzmetal angina market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Prinzmetal angina market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Prinzmetal angina marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Prinzmetal angina market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Prinzmetal angina market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Prinzmetal angina market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Prinzmetal angina across the seven major markets?
What is the number of prevalent cases (2018-2034) of Prinzmetal angina by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Prinzmetal angina by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Prinzmetal angina across the seven major markets?
What is the size of the Prinzmetal angina patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Prinzmetal angina?
What will be the growth rate of patients across the seven major markets?
Prinzmetal Angina: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Prinzmetal angina drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Prinzmetal angina market?
What are the key regulatory events related to the Prinzmetal angina market?
What is the structure of clinical trial landscape by status related to the Prinzmetal angina market?
What is the structure of clinical trial landscape by phase related to the Prinzmetal angina market?
What is the structure of clinical trial landscape by route of administration related to the Prinzmetal angina market?
The Prinzmetal angina market has been comprehensively analyzed in IMARC's new report titled "Prinzmetal Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Prinzmetal angina, also known as variant or vasospastic angina, refers to a form of chest pain or discomfort, which occurs due to a temporary narrowing of the coronary arteries. It is primarily caused by spasms or constrictions of the coronary arteries that can arise even when the person is at rest, making it distinct from other forms of angina. The symptoms of this condition are similar to those of classic angina and include chest pain or discomfort, often described as a tightness, pressure, or squeezing sensation in the chest. The pain typically occurs during rest or sleep and can be more severe. It often happens in episodes, and the pain can also radiate to the neck, jaw, shoulder, or arm. The diagnosis of Prinzmetal angina involves electrocardiograms (ECGs) during chest pain, which can show characteristic changes, such as transient ST-segment elevation. Coronary angiography may also be recommended to assess the condition of the coronary arteries and rule out various other underlying disorders.
The increasing incidences of endothelial dysfunction due to various risk factors, such as smoking, high cholesterol levels, elevated blood pressure, etc., resulting in abnormal responses to certain stimuli and narrowing of blood vessels, are primarily driving the Prinzmetal angina market. In addition to this, the inflating utilization of efficacious medications like calcium channel blockers, nitrates, nitroglycerin, etc., that are aimed at mitigating symptoms and averting further ischemic episodes is creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle adjustments and risk factor management strategies, due to their pivotal role in minimizing the frequency and intensity of vasospastic events, is also bolstering the market growth. Apart from this, the rising usage of cardiac rehabilitation programs, which help in enhancing cardiovascular resilience, optimizing exercise tolerance, and ameliorating overall cardiac function, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of invasive procedures, such as coronary angiography, since they facilitate precise visualization and diagnosis of vasospasms in patients, is also augmenting the market growth. Furthermore, the escalating application of gene-based interventions, entailing the introduction of functional genetic material into cells to rectify or replace the aberrant genes responsible for the condition, is expected to drive the Prinzmetal angina market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Prinzmetal angina market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Prinzmetal angina and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Prinzmetal angina market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Prinzmetal angina market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Prinzmetal angina market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Prinzmetal angina marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Prinzmetal angina market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Prinzmetal angina market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Prinzmetal angina market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Prinzmetal angina across the seven major markets?
What is the number of prevalent cases (2018-2034) of Prinzmetal angina by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Prinzmetal angina by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Prinzmetal angina across the seven major markets?
What is the size of the Prinzmetal angina patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Prinzmetal angina?
What will be the growth rate of patients across the seven major markets?
Prinzmetal Angina: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Prinzmetal angina drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Prinzmetal angina market?
What are the key regulatory events related to the Prinzmetal angina market?
What is the structure of clinical trial landscape by status related to the Prinzmetal angina market?
What is the structure of clinical trial landscape by phase related to the Prinzmetal angina market?
What is the structure of clinical trial landscape by route of administration related to the Prinzmetal angina market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRINZMETAL ANGINA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRINZMETAL ANGINA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRINZMETAL ANGINA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PRINZMETAL ANGINA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRINZMETAL ANGINA - UNMET NEEDS
10 PRINZMETAL ANGINA - KEY ENDPOINTS OF TREATMENT
11 PRINZMETAL ANGINA - MARKETED PRODUCTS
11.1 List of Prinzmetal Angina Marketed Drugs Across the Top 7 Markets
11.1.1 Norvasc (Amlodipine besylate) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Katerzia (Amlodipine) - Azurity Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRINZMETAL ANGINA - PIPELINE DRUGS
12.1 List of Prinzmetal Angina Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 PRINZMETAL ANGINA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 PRINZMETAL ANGINA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRINZMETAL ANGINA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Prinzmetal Angina - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Prinzmetal Angina - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Prinzmetal Angina - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Prinzmetal Angina - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Prinzmetal Angina - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Prinzmetal Angina - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Prinzmetal Angina - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Prinzmetal Angina - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Prinzmetal Angina - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Prinzmetal Angina - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Prinzmetal Angina - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Prinzmetal Angina - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Prinzmetal Angina - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Prinzmetal Angina - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Prinzmetal Angina - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Prinzmetal Angina - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Prinzmetal Angina - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Prinzmetal Angina - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Prinzmetal Angina - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Prinzmetal Angina - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Prinzmetal Angina - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Prinzmetal Angina - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Prinzmetal Angina - Access and Reimbursement Overview
16 PRINZMETAL ANGINA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRINZMETAL ANGINA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRINZMETAL ANGINA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRINZMETAL ANGINA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRINZMETAL ANGINA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRINZMETAL ANGINA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PRINZMETAL ANGINA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRINZMETAL ANGINA - UNMET NEEDS
10 PRINZMETAL ANGINA - KEY ENDPOINTS OF TREATMENT
11 PRINZMETAL ANGINA - MARKETED PRODUCTS
11.1 List of Prinzmetal Angina Marketed Drugs Across the Top 7 Markets
11.1.1 Norvasc (Amlodipine besylate) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Katerzia (Amlodipine) - Azurity Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRINZMETAL ANGINA - PIPELINE DRUGS
12.1 List of Prinzmetal Angina Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 PRINZMETAL ANGINA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 PRINZMETAL ANGINA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRINZMETAL ANGINA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Prinzmetal Angina - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Prinzmetal Angina - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Prinzmetal Angina - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Prinzmetal Angina - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Prinzmetal Angina - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Prinzmetal Angina - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Prinzmetal Angina - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Prinzmetal Angina - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Prinzmetal Angina - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Prinzmetal Angina - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Prinzmetal Angina - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Prinzmetal Angina - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Prinzmetal Angina - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Prinzmetal Angina - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Prinzmetal Angina - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Prinzmetal Angina - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Prinzmetal Angina - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Prinzmetal Angina - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Prinzmetal Angina - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Prinzmetal Angina - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Prinzmetal Angina - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Prinzmetal Angina - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Prinzmetal Angina - Access and Reimbursement Overview
16 PRINZMETAL ANGINA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRINZMETAL ANGINA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRINZMETAL ANGINA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
